BZW1 Knockout HeLa Polyclonal Cells are a proliferating, CRISPR/Cas9-edited polyclonal population derived from HeLa cells, designed for targeted disruption of the BZW1 locus. This product provides a pooled knockout model, circumventing clonal selection, to study loss-of-function effects of BZW1, a translation initiation factor. The editing is achieved via transient delivery of Cas9 ribonucleoproteins targeting critical exons, yielding a heterogeneous mixture of indel-containing alleles. These polyclonal cells are ideal for dissecting BZW1-dependent translation control in a reproducible and scalable format.
The parental HeLa line is an immortalized human epithelial cell line originating from a cervical adenocarcinoma and harbors integrated HPV18 sequences. It remains one of the most utilized models in cancer biology due to its robust growth, well-annotated genome, and susceptibility to genetic manipulation. HeLa cells exhibit dysregulated signaling networks, including mTOR and translational machinery, making them particularly relevant for exploring how BZW1 modulates protein synthesis in a cancer context. Their HPV18 status further offers a platform to probe virus-host interactions in translation.
BZW1 acts as a cofactor that potentiates eIF3 recruitment to mRNAs, with a preference for those possessing structured 5′ untranslated regions. This function is under the control of the mTORC1 kinase, which integrates growth factors and nutrients, and is also responsive to cellular stress inputs. BZW1 physically interacts with eIF3 and collaborates with canonical factors such as eIF4E and the stress-sensitive eIF2??. Downstream, it promotes ribosomal protein S6K activation and the translation of proteins that drive cell proliferation and survival, thereby bridging mTOR/eIF2 signaling to translational output.
In the HeLa environment, elimination of BZW1 is expected to selectively suppress translation of mRNAs with complex 5′ leaders, many of which encode oncoproteins, cyclins, and anti-apoptotic factors. This disruption can unmask translational vulnerabilities specific to HPV-positive adenocarcinoma cells. Consequently, the polyclonal knockout model serves as a tool to dissect the contribution of BZW1 to tumorigenic growth, to examine how mTORC1 and eIF2?? signals are channeled through BZW1, and to evaluate whether BZW1 loss influences cell responses to chemotherapeutic or targeted agents that stress translation.
Researchers can employ a suite of assays with these cells, including polysome gradient fractionation to map translating ribosomes, ribosome footprinting for codon-resolution occupancy, and puromycin incorporation to gauge global protein synthesis rates. Additional methods such as western blotting for candidate proteins (e.g., MYC, cyclin D1), RT-qPCR for mRNA levels, and luciferase reporter assays with structured 5′ UTRs enable precise mechanistic delineation. These applications position the BZW1 knockout cells for use in drug target validation, translational control studies, and cancer biology investigations. For further information, contact Ascent Research.
